Evaluating plasma phoenixin-14, galanin, galanin-like peptide, and spexin levels in polycystic ovary syndrome.

Authors

Meltem Yardim, Huseyin Fatih Gul, Ulku Ayse Turker Aras

Published in

Irish journal of medical science. Sep 24, 2025. Epub Sep 24, 2025.

Abstract

Impaired central neuropeptide production is implicated in polycystic ovary syndrome (PCOS).
This study aimed to determine whether plasma phoenixin-14, galanin (GAL), galanin-like peptide (GALP), and spexin levels in women with PCOS were altered compared to those in non-PCOS controls.
Sixty participants, including 30 patients diagnosed with PCOS and 30 healthy controls, were enrolled in this study. Phoenixin-14, GAL, GALP, and spexin levels were measured in plasma samples.
Although plasma phoenixin-14 levels in the PCOS group were significantly higher than those in the control group, spexin and GAL levels were significantly lower. No significant intergroup differences were observed in plasma GALP levels (p = 0.442). To distinguish PCOS from healthy controls, the area under the receiver operating characteristic (ROC) curve (AUC) of phoenixin-14 was 0.798, that of spexin was 0.757, and that of GAL was 0.702 (p < 0.001, p < 0.001, and p = 0.003, respectively). The AUC of the combined diagnostic value of the three peptides for PCOS was 0.910 (95%CI: 0.808-0.968) (p < 0.001), indicating a good diagnostic value.
Plasma phoenixin-14, spexin, and GAL levels differed between patients with PCOS and controls. When combined, the three peptides exhibited better predictive performance than the individual peptides.

PMID:
40991186
Bibliographic data and abstract were imported from PubMed on 24 Sep 2025.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.